参考文献/References:
[1] Rangaswami J,Bhalla V,Blair J,et al. Cardiorenal syndrome:classification,pathophysiology,diagnosis,and treatment strategies:a scientific statement from the American Heart Association[J]. Circulation,2019,139(16):e840-e878.
[2] Kim JA,Wu L,Rodriguez M,et al. Recent developments in the evaluation and management of cardiorenal syndrome:a comprehensive review[J]. Curr Probl Cardiol,2023,48(3):101509.
[3] Kumar U,Wettersten N,Garimella PS. Cardiorenal syndrome:pathophysiology[J]. Cardiol Clin,2019,37(3):251-265.
[4] Marx N,Federici M,Schütt K,et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes[J]. Eur Heart J,2023,44(39):4043-4140.
[5] Zinman B,Wanner C,Lachin JM,et al. Empagliflozin,cardiovascular outcomes,and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
[6] Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.
[7] Wiviott SD,Raz I,Bonaca MP,et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med,2019,380(4):347-357.
[8] Perkovic V,Jardine MJ,Neal B,et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med ,2019,380(24):2295-2306.
[9] Heerspink HJL,Stefánsson BV,Correa-Rotter R,et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med,2020,383(15):1436-1446.
[10] Herrington WG,Staplin N,Wanner C,et al. Empagliflozin in patients with chronic kidney disease[J]. N Engl J Med,2023,388(2):117-127.
[11] Darmon M,Schetz M. What’s new in cardiorenal syndrome?[J]. Intensive Care Med,2018,44(6):908-910.
[12] Yurista SR,Silljé H,van Goor H,et al. Effects of sodium-glucose co-transporter 2 inhibition with empaglifozin on renal structure and function in non-diabetic rats with left ventricular dysfunction after myocardial infarction[J]. Cardiovasc Drugs Ther,2020,34(3):311-321.
[13] Hallow KM,Helmlinger G,Greasley PJ,et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis[J]. Diabetes Obes Metab,2018,20(3):479-487.
[14] Hou YC,Zheng CM,Yen TH,et al. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection[J]. Int J Mol Sci ,2020,21(21):7833.
[15] Santos-Gallego CG,Requena-Ibanez JA,San Antonio R,et al. Empagliflozin ameliorates adverse left?ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics[J]. J Am Coll Cardiol,2019,73(15):1931-1944.
[16] Mancia G,Rea F,Ludergnani M,et al. Renin-angiotensin-aldosterone system blockers and the risk of covid-19[J]. N Engl J Med,2020,382(25):2431-2440.
[17] Salvatore T,Galiero R,Caturano A,et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors[J]. Int J Mol Sci,2022,23(7):3651.
[18] Theofilis P,Sagris M,Oikonomou E,et al. The impact of SGLT2 inhibitors on inflammation:A systematic review and meta-analysis of studies in rodents[J]. Int Immunopharmacol,2022,111:109080.
[19] Virzì GM, Clementi A, de Cal M, et al. Oxidative stress: dual pathway induction in cardiorenal syndrome type 1 pathogenesis[J]. Oxid Med Cell Longev, 2015,2015:391790.
[20] Balogh DB,Wagner LJ,Fekete A. An overview of the cardioprotective effects of novel antidiabetic classes:focus on inflammation,oxidative stress,and fibrosis[J]. Int J Mol Sci,2023,24(9):7789.
[21] El-Shafey M,El-Agawy M,Eldosoky M,et al. Role of dapagliflozin and liraglutide on diabetes-induced cardiomyopathy in rats:implication of oxidative stress,inflammation,and apoptosis[J]. Front Endocrinol (Lausanne),2022,13:862394.
[22] Winiarska A,Knysak M,Nabrdalik K,et al. Inflammation and oxidative stress in diabetic kidney disease:the targets for SGLT2 inhibitors and GLP-1 receptor agonists[J]. Int J Mol Sci,2021,22(19):10822.
[23] Pignatelli P,Baratta F,Buzzetti R,et al. The sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce platelet activation and thrombus formation by lowering NOX2-related oxidative stress:a pilot study[J]. Antioxidants (Basel),2022,11(10):1878.
[24] Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney:modulation by SGLT2 inhibitors and hypoxia mimetics[J]. Am J Kidney Dis,2021,77(2):280-286.
[25] Stefánsson BV,Heerspink H,Wheeler DC,et al. Correction of anemia by dapagliflozin in patients with type 2 diabetes[J]. J Diabetes Complications,2020,34(12):107729.
[26] Sano M,Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects[J]. Circulation,2019,139(17):1985-1987.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(5):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(5):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(5):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]